Special Issue

Neurological Diseases: From Molecular Mechanisms to Clinical Practice

Message from the Guest Editors

The increasing incidence of neurological diseases in young people together with the population's aging, as well as discovery of new mutations that cause neurological disorders are not good indicators for the future. Unfortunately, effective methods of neuroprotection are lacking. The available therapies reduce the neurodegeneration rate to a certain extent but cannot cure or significantly slow down a disease. Many suggested agents were found to protect nerve cells in vitro and in animal brain but were ineffective or caused unacceptable side effects in humans. To find effective neuroprotectors, a profound study of the molecular mechanisms of neurodegeneration and neuroprotection is needed. Between the initial processes leading to damage propagation and the final processes resulting in neurodegeneration or neuroprotection with brain tissue recovery lies a vast field of biochemical signaling connected with transcription and epigenetic mechanisms. This Special Issue will collect reviews and original articles on new approaches to find promising strategies for treating neuropathologies.

Guest Editors

Dr. Svetlana Viktorovna Demyanenko Academy of Biology and Biotechnology, Southern Federal University, 344090 Rostov-on-Don, Russia

Dr. Denis Silachev

1. Laboratory of the Structure and Function of Mitochondria, A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia 2. Lab Stem Cells Technology, V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, 117997 Moscow, Russia

Deadline for manuscript submissions

closed (25 August 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/134264

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).